Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 89.4% in November

Xilio Therapeutics, Inc. (NASDAQ:XLO) saw a large decrease in short interest in November. As of November 15th, there was short interest totalling 42,000 shares, a decrease of 89.4% from the October 31st total of 396,100 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average trading volume of 263,800 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Investors Weigh In On Xilio Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC boosted its stake in Xilio Therapeutics by 18.3% during the 2nd quarter. Renaissance Technologies LLC now owns 295,000 shares of the company’s stock valued at $280,000 after purchasing an additional 45,554 shares during the period. XTX Topco Ltd acquired a new position in shares of Xilio Therapeutics during the second quarter worth approximately $32,000. Finally, Geode Capital Management LLC boosted its position in shares of Xilio Therapeutics by 85.0% in the third quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock valued at $266,000 after acquiring an additional 155,337 shares during the period. 54.29% of the stock is owned by institutional investors and hedge funds.

Xilio Therapeutics Price Performance

Shares of XLO opened at $1.01 on Friday. The company has a market capitalization of $44.40 million, a PE ratio of -0.59 and a beta of -0.24. Xilio Therapeutics has a one year low of $0.49 and a one year high of $1.93. The company’s fifty day moving average price is $0.93 and its 200 day moving average price is $0.94.

Analysts Set New Price Targets

Separately, Raymond James lowered their price target on Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a report on Friday, November 8th.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.